Sublingual immunotherapy for allergic rhinitis: where are we now?

Area of Science:

• Allergy and Immunology
• Pharmacology

Background:

• Sublingual immunotherapy (SLIT) emerged in the 1980s as a safer alternative to subcutaneous immunotherapy.
• Recent advancements have significantly improved SLIT preparations, particularly tablet formulations meeting regulatory standards.

Purpose of the Study:

• To review the efficacy and cost-effectiveness of sublingual immunotherapy (SLIT) for allergic rhinitis.
• To highlight the development and availability of optimal SLIT products for grass-pollen allergies.

Main Methods:

• Review of meta-analyses supporting SLIT efficacy in allergic rhinitis.
• Examination of regulatory requirements for allergen extract quality in SLIT tablet development.
• Analysis of cost-effectiveness data comparing SLIT with drug treatment.

Main Results:

• SLIT demonstrates proven efficacy for allergic rhinitis, supported by meta-analyses.
• Optimized SLIT tablet preparations are available for grass-pollen-induced allergic rhinitis.
• SLIT exhibits significant cost-effectiveness, with savings up to 80% compared to drug treatment.

Conclusions:

• Sublingual immunotherapy (SLIT) is an effective and safe treatment option for allergic rhinitis.
• SLIT offers substantial cost savings, making it a financially viable long-term allergy management strategy.
• Further development of SLIT preparations for other allergens is ongoing.